Mtor - mechanistic target of rapamycin kinase Gene

中文名称：雷帕霉素激酶的机制靶点

种属: Mus musculus

同用名: FRAP; flat; FRAP2; Frap1; RAFT1; RAPT1; 2610315D21Rik

基因 ID: 56717 | 基因类型: protein coding

关于 Mtor

Chromosome 4: 148,533,068-148,642,140 forward strand.GRCm39:CM000997.3

This gene has 4 transcripts (splice variants), 217 orthologues, 5 paralogues and is associated with 64 phenotypes. Ubiquitous expression in testis adult (RPKM 23.), kidney adult (RPKM 12.8) and 28 other tissues.

功能概要

该基因编码的蛋白可启动蛋白质丝氨酸/苏氨酸激酶活性和核糖体结合活性。参与多个过程，包括“从头”嘧啶核碱基生物合成过程； T-helper 1 细胞谱系承诺；和神经元动作电位。作用于多个过程的上游或内部，包括心脏发育；细胞成分生物合成的正向调节；和蛋白质磷酸化的调节。位于胞质溶胶中；树突;和核。 TORC1 复合体的一部分。与 PML 体共定位。在中枢神经系统中表达；早孕;卵母细胞;呼吸系统;和视网膜。该基因的人类直系同源物与常染色体显性多囊肾病有关；肾血管平滑肌脂肪瘤;肺部疾病（多发）；前列腺癌;和 2 型糖尿病。与人 mTOR 同源（雷帕霉素激酶的机制靶标）。 [由基因组资源联盟提供，2022 年 4 月]

Enables protein serine/threonine kinase activity and ribosome binding activity. Involved in several processes, including 'de novo' pyrimidine nucleobase biosynthetic process; T-helper 1 cell lineage commitment; and neuronal action potential. Acts upstream of or within several processes, including heart development; positive regulation of cellular component biogenesis; and regulation of protein phosphorylation. Located in cytosol; dendrite; and nucleus. Part of TORC1 complex. Colocalizes with PML body. Is expressed in central nervous system; early conceptus; oocyte; respiratory system; and retina. Human ortholog(s) of this gene implicated in autosomal dominant polycystic kidney disease; kidney angiomyolipoma; lung disease (multiple); prostate cancer; and type 2 diabetes mellitus. Orthologous to human mTOR (mechanistic target of rapamycin kinase). [provided by Alliance of Genome Resources, Apr 2022]

Mtor 基因产物(1)

mRNA	Protein	Name
NM_020009.2	NP_064393.2	serine/threonine-protein kinase mTOR

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables protein binding	IPI IPI: 通过物理相互作用推断	12150926	MGI
enables protein serine/threonine kinase activity	IDA IDA: 通过直接分析推断	11707573	MGI
enables ribosome binding	IDA IDA: 通过直接分析推断	21045808	MGI

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in 'de novo' pyrimidine nucleobase biosynthetic process	IDA IDA: 通过直接分析推断	23429704	MGI
involved in T-helper 1 cell lineage commitment	IMP IMP: 通过突变表型推断	26410627	MGI
involved in TOR signaling	IGI IGI: 通过遗传相互作用推断	26160071	MGI
involved in TOR signaling	IMP IMP: 通过突变表型推断	15485918	MGI
involved in behavioral response to pain	IGI IGI: 通过遗传相互作用推断	31874168	MGI
acts upstream of calcineurin-NFAT signaling cascade	IMP IMP: 通过突变表型推断	18347059	MGI
involved in cardiac cell development	IMP IMP: 通过突变表型推断	23342106	MGI
acts upstream of or within cardiac muscle cell development	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within cardiac muscle contraction	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within cardiac muscle tissue development	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within cell projection organization	IMP IMP: 通过突变表型推断	16286931	MGI
involved in cellular response to hypoxia	IDA IDA: 通过直接分析推断	16915281	MGI
involved in cellular response to nutrient levels	IDA IDA: 通过直接分析推断	21258367	MGI
acts upstream of or within energy reserve metabolic process	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within germ cell development	IDA IDA: 通过直接分析推断	12140361	MGI
acts upstream of or within heart morphogenesis	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within heart valve morphogenesis	IMP IMP: 通过突变表型推断	25139234	MGI
involved in inflammatory response	IGI IGI: 通过遗传相互作用推断	31874168	MGI
acts upstream of macroautophagy	IMP IMP: 通过突变表型推断	16714284	MGI
acts upstream of or within multicellular organism growth	IMP IMP: 通过突变表型推断	25139234	MGI
involved in negative regulation of autophagy	IMP IMP: 通过突变表型推断	21258367	MGI
acts upstream of or within negative regulation of calcineurin-NFAT signaling cascade	IMP IMP: 通过突变表型推断	18347059	MGI
acts upstream of or within negative regulation of cell size	IGI IGI: 通过遗传相互作用推断	15185396	MGI
acts upstream of or within negative regulation of macroautophagy	IMP IMP: 通过突变表型推断	16714284	MGI
involved in neuronal action potential	IGI IGI: 通过遗传相互作用推断	31874168	MGI
acts upstream of oligodendrocyte differentiation	IMP IMP: 通过突变表型推断	25411504	MGI
involved in peptidyl-serine phosphorylation	IDA IDA: 通过直接分析推断	24011591	MGI
acts upstream of or within peptidyl-serine phosphorylation	IMP IMP: 通过突变表型推断	18347059	MGI
acts upstream of or within peptidyl-threonine phosphorylation	IDA IDA: 通过直接分析推断	11707573	MGI
acts upstream of or within positive regulation of actin filament polymerization	IDA IDA: 通过直接分析推断	15467718	MGI
acts upstream of or within positive regulation of actin filament polymerization	IMP IMP: 通过突变表型推断	15467718	MGI
acts upstream of or within positive regulation of lamellipodium assembly	IDA IDA: 通过直接分析推断	15467718	MGI
acts upstream of or within positive regulation of myotube differentiation	IGI IGI: 通过遗传相互作用推断	19704009	MGI
acts upstream of or within positive regulation of oligodendrocyte differentiation	IMP IMP: 通过突变表型推断	25411504	MGI
acts upstream of or within positive regulation of peptidyl-tyrosine phosphorylation	IMP IMP: 通过突变表型推断	15467718	MGI
acts upstream of or within positive regulation of protein phosphorylation	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within positive regulation of stress fiber assembly	IDA IDA: 通过直接分析推断	15467718	MGI
acts upstream of or within post-embryonic development	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within regulation of GTPase activity	IMP IMP: 通过突变表型推断	15467718	MGI
involved in regulation of autophagy	IDA IDA: 通过直接分析推断	24011591	MGI
involved in regulation of circadian rhythm	IMP IMP: 通过突变表型推断	29750810	MGI
involved in regulation of locomotor rhythm	IMP IMP: 通过突变表型推断	29750810	MGI
acts upstream of or within regulation of membrane permeability	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within regulation of myelination	IMP IMP: 通过突变表型推断	24101522	MGI
involved in regulation of osteoclast differentiation	IDA IDA: 通过直接分析推断	19440205	MGI
acts upstream of or within regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: 通过突变表型推断	25139234	MGI
acts upstream of or within regulation of protein kinase activity	IGI IGI: 通过遗传相互作用推断	15185396	MGI
acts upstream of or within regulation of protein phosphorylation	IDA IDA: 通过直接分析推断	17556672	MGI
acts upstream of or within response to amino acid	IDA IDA: 通过直接分析推断	15467718	MGI
involved in response to heat	IGI IGI: 通过遗传相互作用推断	31874168	MGI
acts upstream of or within response to insulin	IDA IDA: 通过直接分析推断	15467718	MGI
acts upstream of or within ruffle organization	IDA IDA: 通过直接分析推断	15467718	MGI
acts upstream of or within voluntary musculoskeletal movement	IMP IMP: 通过突变表型推断	25139234	MGI

细胞组分 GO 注释	逻辑证据	参考文献	来源
colocalizes with PML body	IDA IDA: 通过直接分析推断	16915281	MGI
part of TORC1 complex	IDA IDA: 通过直接分析推断	12718876	MGI
located in cytosol	IDA IDA: 通过直接分析推断	16915281	MGI
located in dendrite	IDA IDA: 通过直接分析推断	23836929	MGI
located in nucleus	IDA IDA: 通过直接分析推断	18347059	MGI

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Mtor 蛋白结构

TEL1

HEAT

0
400
800
1200
1600
2000
2400
2549 a.a.

蛋白主名

其他名称

serine/threonine-protein kinase mTOR

FK506 binding protein 12-rapamycin associated protein 1	FK506-binding protein 12-rapamycin complex-associated protein 1
FKBP-rapamycin associated protein (FRAP)	FKBP12-rapamycin complex-associated protein
angiopoietin-like factor CDT6	mammalian target of rapamycin
mechanistic target of rapamycin (serine/threonine kinase)	rapamycin target protein 1

相关产品

Approval

生物活性分子 (9)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10219	Rapamycin	Inhibitor	99.94%	是
HY-10218	Everolimus	Inhibitor	99.85%	是
HY-50910	Temsirolimus	Inhibitor	99.56%	是
HY-N0486	L-Leucine	Activator	99.79%	否
HY-N0281	Daphnetin	Inhibitor	99.86%	否
HY-B0766	Bicyclol		99.91%	否
HY-B1232A	Metyrapone Tartrate	Modulator	/	否
HY-B0725A	Doxepin		/	否
HY-10218R	Everolimus (Standard)	Inhibitor	/	否

Clinical Phase

生物活性分子 (30)

目录号	产品名	作用方式	纯度	Phase
HY-10219G	Rapamycin (GMP)	Inhibitor	/	Phase 4
HY-50673	Dactolisib	Inhibitor	99.94%	Phase 3
HY-10681	Gedatolisib	Inhibitor	99.68%	Phase 3
HY-15174	Dactolisib Tosylate	Inhibitor	99.87%	Phase 3
HY-50908	Ridaforolimus	Inhibitor	99.28%	Phase 3
HY-13328	Sapanisertib	Inhibitor	99.66%	Phase 2
HY-139609	Camonsertib	Inhibitor	99.75%	Phase 2
HY-N0112	Dihydromyricetin	Inhibitor	98.10%	Phase 2
HY-114384	NV-5138	Activator	≥98.0%	Phase 2
HY-15247	Vistusertib	Inhibitor	98.91%	Phase 2
HY-12513	Samotolisib	Inhibitor	99.27%	Phase 2
HY-15177	PF-04691502	Inhibitor	99.91%	Phase 2
HY-114384B	NV-5138 hydrochloride	Activator	≥98.0%	Phase 2
HY-13246	Apitolisib	Inhibitor	99.29%	Phase 2
HY-16962	CC-115	Inhibitor	99.82%	Phase 2
HY-15900	Voxtalisib	Inhibitor	98.81%	Phase 2
HY-13334A	BGT226	Inhibitor	99.51%	Phase 2
HY-16956	Onatasertib	Inhibitor	99.13%	Phase 2
HY-12868	Bimiralisib	Inhibitor	99.80%	Phase 2
HY-13334	BGT226 maleate	Inhibitor	99.87%	Phase 2
HY-16962A	CC-115 hydrochloride	Inhibitor	98.03%	Phase 2
HY-13691	MKC-1	Inhibitor	99.23%	Phase 2
HY-10422	AZD-8055	Inhibitor	99.60%	Phase 1
HY-132168	RMC-5552	Inhibitor	98.10%	Phase 1
HY-10297	Omipalisib	Inhibitor	99.93%	Phase 1
HY-12036	GSK1059615	Inhibitor	≥99.0%	Phase 1
HY-10423	OSI-027	Inhibitor	99.40%	Phase 1
HY-16585	VS-5584	Inhibitor	99.14%	Phase 1
HY-15248	GDC-0349	Inhibitor	98.02%	Phase 1
HY-14581	Palomid 529	Inhibitor	99.47%	Phase 1

Pre-clinical Phase

生物活性分子 (210)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-B0795	MHY1485	Activator	99.86%	否
HY-13003	Torin 1	Inhibitor	99.08%	否
HY-N0109	Salidroside	Activator	99.79%	否
HY-13002	Torin 2	Inhibitor	99.65%	否
HY-U00434	3BDO	Activator	99.93%	否
HY-10115	PI-103	Inhibitor	98.93%	否
HY-122022	JR-AB2-011	Inhibitor	99.16%	否
HY-111373	RapaLink-1	Inhibitor	99.27%	否
HY-10474	Torkinib	Inhibitor	98.37%	否
HY-100542	D-α-Hydroxyglutaric acid disodium	Inhibitor	≥98.0%	否
HY-124719	hSMG-1 inhibitor 11j	Inhibitor	99.82%	否
HY-N0189	Aloe emodin	Inhibitor	98.32%	否
HY-124798	Rheb inhibitor NR1	Inhibitor	99.46%	否
HY-N0047	Polyphyllin I	Inhibitor	99.89%	否
HY-116522	AR420626		98.29%	否
HY-N0787	Cryptochlorogenic acid	Inhibitor	99.87%	否
HY-50710	KU-0063794	Inhibitor	99.55%	否
HY-W012722	4-Methyl-2-oxopentanoic acid	Inhibitor	99.51%	否
HY-124760	hSMG-1 inhibitor 11e	Inhibitor	99.81%	否
HY-155747	FDW028	Inhibitor	99.51%	否
HY-19962	Paxalisib	Inhibitor	99.63%	是
HY-134904	RMC-6272	Inhibitor	95.54%	否
HY-10044	WYE-132	Inhibitor	99.90%	否
HY-N0486S9	L-Leucine-d3	Activator	≥98.0%	否
HY-N0486S1	L-Leucine-13C	Activator	99.4%	否
HY-N6626	Pyraclostrobin		99.91%	否
HY-10372	PP121	Inhibitor	98.67%	否
HY-18353	mTOR inhibitor-3	Inhibitor	99.09%	否
HY-13431	KU-0060648	Inhibitor	99.62%	否
HY-10683	PKI-402	Inhibitor	98.43%	否
HY-115449	Chromeceptin	p53 Inhibitor	99.91%	否
HY-146751	PI3K/Akt/mTOR-IN-2	Inhibitor	99.86%	否
HY-W016412	Coenzyme Q0	Inhibitor	99.88%	否
HY-100222	CZ415	Inhibitor	98.39%	否
HY-12763	GNE-317	Inhibitor	99.14%	否
HY-N6996	Methyl Eugenol	Inhibitor	99.79%	否
HY-W592871	10-Hydroxy-2-decenoic acid		99.99%	否
HY-107365	PQR530	Inhibitor	99.98%	否
HY-10115A	PI-103 Hydrochloride	Inhibitor	98.00%	否
HY-10219S	Rapamycin-d3	Inhibitor	95.48%	否
HY-N0107	Cyclovirobuxine D	Inhibitor	≥98.0%	否
HY-N0656A	(+)-Usnic acid	Inhibitor	99.63%	否
HY-12034	WYE-354	Inhibitor	98.04%	否
HY-N2217	Rotundic acid	Inhibitor	99.41%	否
HY-15521	ETP-46464	Inhibitor	99.55%	否
HY-156671	RMC-4998	Inhibitor	96.33%	否
HY-15272	WAY-600	Inhibitor	99.75%	否
HY-N0486S3	L-Leucine-15N	Activator	≥98.0%	否
HY-100026	PQR620	Inhibitor	98.01%	否
HY-137175	TMBIM6 antagonist-1	Antagonist	99.60%	否
HY-N0486S	L-Leucine-d10	Activator	≥98.0%	否
HY-N0486S8	L-Leucine-13C6,15N	Activator	99.90%	否
HY-10811	GNE-493	Inhibitor	/	否
HY-114414	HDACs/mTOR Inhibitor 1	Inhibitor	99.01%	否
HY-109046	Tulrampator		98.92%	否
HY-11080	PKI-179	Inhibitor	≥98.0%	否
HY-W058849	MT 63-78	Inhibitor	98.50%	否
HY-N6843	Arnicolide D	Inhibitor	99.20%	否
HY-118717	mTOR inhibitor WYE-28	Inhibitor	99.75%	否
HY-100470	NSC781406	Inhibitor	99.97%	否
HY-100398	PF-04979064	Inhibitor	99.54%	否
HY-110109	ETP-45658	Inhibitor	98.97%	否
HY-N6950	Hederacolchiside A1	Modulator	99.69%	否
HY-11042	GNE-477	Inhibitor	98.75%	否
HY-111508	PI3K/mTOR Inhibitor-2	Inhibitor	99.10%	否
HY-128333	PI3K/mTOR Inhibitor-4	Inhibitor	97.00%	否
HY-N1050	Zederone	Inhibitor	99.61%	否
HY-15271	WYE-687	Inhibitor	98.05%	否
HY-13806	XL388	Inhibitor	99.74%	否
HY-112914	mTOR inhibitor-1	Inhibitor	98.82%	否
HY-126077	MTI-31	Inhibitor	99.98%	否
HY-12652	AZD3147	Inhibitor	99.93%	否
HY-124582	NEO214	Activator	≥98.0%	否
HY-N9942	Physalin A	Inhibitor	99.22%	否
HY-131344	mTOR inhibitor-8	Inhibitor	97.08%	否
HY-136660	PQR626	Inhibitor	98.05%	否
HY-137315	TML-6	Inhibitor	99.01%	否
HY-163198	ASCT2-IN-1	Inhibitor	98.21%	否
HY-N0486S2	L-Leucine-13C6	Activator	≥98.0%	否
HY-122665	HTH-01-091	Inhibitor	98.64%	否
HY-163199	ASCT2-IN-2	Inhibitor	99.10%	否
HY-134903	(32-Carbonyl)-RMC-5552	Inhibitor	95.41%	否
HY-151622	PI3K/mTOR Inhibitor-11	Inhibitor	98.74%	否
HY-124036	DS-7423	Inhibitor	99.75%	否
HY-107363	FT-1518	Inhibitor	98.14%	否
HY-114267	Cbz-B3A	Inhibitor	≥98.0%	否
HY-153120A	PI3K/mTOR Inhibitor-13 sodium	Inhibitor	98.13%	否
HY-162382	KTC1101	Inhibitor	98.09%	否
HY-145931	CC214-2	Inhibitor	98.41%	否
HY-N2590	Lupenone		99.74%	否
HY-W348485	WRX606	Inhibitor	95.65%	否
HY-159480	AD1058	Inhibitor	/	否
HY-11080A	PKI-179 hydrochloride	Inhibitor	99.66%	否
HY-141805	MHY-1685	Inhibitor	99.97%	否
HY-125927	8-Aminoadenosine	Inhibitor	99.94%	否
HY-111065	OXA-01	Inhibitor	/	否
HY-101776A	Desmethyl-VS-5584 hydrochloride	Inhibitor	98.63%	否
HY-10219GL	Rapamycin (GMP Like)	Inhibitor	98.8%	否
HY-N3628	Coronarin A	Inhibitor	≥98.0%	否
HY-155066	FD274	Inhibitor	/	否
HY-B1787	Sulindac sulfone	Inhibitor	98.08%	否
HY-109633	PI3K-IN-18	Inhibitor	≥99.0%	否
HY-122665A	HTH-01-091 TFA	Inhibitor	99.48%	否
HY-N4315	Pomiferin	Inhibitor	98.98%	否
HY-157169	IBL-302	Inhibitor	98.21%	否
HY-15271A	WYE-687 dihydrochloride	Inhibitor	≥98.0%	否
HY-N0486S12	L-Leucine-d2	Activator	≥99.0%	否
HY-143510	RMC-4627		99.20%	否
HY-N5136	25(R,S)-Ruscogenin	Inhibitor	98.59%	否
HY-147284	PI3K-IN-37	Inhibitor	≥99.0%	否
HY-10620	PI3K-IN-22	Inhibitor	99.50%	否
HY-U00326	PI3Kα/mTOR-IN-1	Inhibitor	99.30%	否
HY-10812	GNE-490	Inhibitor	96.29%	否
HY-151137	HSP90/mTOR-IN-1	Inhibitor	/	否
HY-10218S	Everolimus-d4	Inhibitor	97.88%	否
HY-119665	Asteltoxin	Inhibitor	/	否
HY-139832	MCX 28	Inhibitor	/	否
HY-161509	PT-88	Inhibitor	/	否
HY-128027	eCF309	Inhibitor	98.2%	否
HY-147913	PI3K/Akt/mTOR-IN-3	Inhibitor	/	否
HY-144687	ATM Inhibitor-4	Inhibitor	/	否
HY-146016	PI3K/mTOR Inhibitor-5	Inhibitor	/	否
HY-N0486S10	L-Leucine-18O2	Activator	/	否
HY-154910	CC214-1	Inhibitor	/	否
HY-N0486S6	L-Leucine-2-13C,15N	Activator	/	否
HY-163511	PI3K/Akt/mTOR-IN-4	Inhibitor	/	否
HY-161856	Antifungal agent 106	Inhibitor	/	否
HY-150061	NVP-BBD130	Inhibitor	/	否
HY-169100	Antiproliferative agent-57		/	否
HY-155376	mTOR inhibitor-14	Inhibitor	/	否
HY-RS08811	Mtor Mouse Pre-designed siRNA Set A	Inhibitor	/	否
HY-N10754	Aschantin	Inhibitor	/	否
HY-160548	mTOR inhibitor-18	Inhibitor	/	否
HY-N2517	Dihydroevocarpine	Inhibitor	99.62%	否
HY-15281	QL-IX-55	Inhibitor	/	否
HY-RS08812	Mtor Rat Pre-designed siRNA Set A	Inhibitor	/	否
HY-15901	LGB321	Inhibitor	/	否
HY-141476	PI3K/mTOR Inhibitor-3	Inhibitor	/	否
HY-162147	Nur77 modulator 3	Inhibitor	99.01%	否
HY-N0486S13	L-Leucine-15N,d10		/	否
HY-13847	GNE-555	Inhibitor	/	否
HY-162143	SKI-349	Inhibitor	99.58%	否
HY-101776	Desmethyl-VS-5584	Inhibitor	/	否
HY-169022	4-FPBUA	Inhibitor	/	否
HY-141701	mTOR/HDAC-IN-1	Inhibitor	/	否
HY-118712	mTOR inhibitor WYE-23	Inhibitor	/	否
HY-113038	D-α-Hydroxyglutaric acid	Inhibitor	/	否
HY-137315S	TML-6-d3		/	否
HY-N0486S4	L-Leucine-d7	Activator	/	否
HY-154958	mTOR inhibitor-12	Inhibitor	/	否
HY-18953	mTOR inhibitor-23	Inhibitor	/	否
HY-P5984	Thioether-cyclized helix B peptide, CHBP	Inhibitor	/	否
HY-147285	PI3K/mTOR Inhibitor-9	Inhibitor	/	否
HY-15269	PP30	Inhibitor	/	否
HY-118704	P-2281	Inhibitor	99.81%	否
HY-147614	PI3K/mTOR Inhibitor-7	Inhibitor	/	否
HY-154957	mTOR inhibitor-11	Inhibitor	/	否
HY-N0486S7	L-Leucine-1-13C,15N	Activator	≥98.0%	否
HY-P1823	C-Reactive Protein (CRP) (174-185)	Modulator	99.83%	否
HY-N0486S11	L-Leucine-d1	Activator	/	否
HY-137996	Dehydrovomifoliol	Inhibitor	/	否
HY-115869	RMC-4529	Inhibitor	/	否
HY-127067	Yuanhuadin	Inhibitor	/	否
HY-156027	SIRT6-IN-3	Inhibitor	/	否
HY-125535	OSU-53	Inhibitor	/	否
HY-146200	PI3K/mTOR Inhibitor-8	Inhibitor	/	否
HY-151915	ATR-IN-20	Inhibitor	/	否
HY-159517	PI3K/Akt/mTOR-IN-5	Inhibitor	/	否
HY-P10323	T7 Peptide	Inhibitor	/	否
HY-N1244	Sarmentosin	Inhibitor	/	否
HY-159577	Nic-15	Modulator	/	否
HY-147613	PI3K/mTOR Inhibitor-6	Inhibitor	/	否
HY-156432	ALK-IN-26	Inhibitor	99.87%	否
HY-N6626R	Pyraclostrobin (Standard)		/	否
HY-156445	PI3K/mTOR Inhibitor-14	Inhibitor	/	否
HY-147966	HDAC-IN-43	Inhibitor	/	否
HY-144295	PI3Kα-IN-5	Inhibitor	/	否
HY-144449	mTOR/HDAC6-IN-1	Inhibitor	/	否
HY-121726	3HOI-BA-01	Inhibitor	/	否
HY-144686	ATM Inhibitor-3	Inhibitor	/	否
HY-152238	PI3K/mTOR Inhibitor-12	Inhibitor	/	否
HY-P5984A	Thioether-cyclized helix B peptide, CHBP TFA	Inhibitor	/	否
HY-155721	22-(4′-py)-JA	Inhibitor	/	否
HY-N1338	Royleanone	Inhibitor	/	否
HY-N0486S5	L-Leucine-2-13C	Activator	/	否
HY-10116	PI-540	Inhibitor	/	否
HY-15268	PP487	Inhibitor	/	否
HY-161857	Akt/mTOR-IN-1	Inhibitor	/	否
HY-RS08810	MTOR Human Pre-designed siRNA Set A	Inhibitor	/	否
HY-15901A	LGB321 monohydrochloride	Inhibitor	/	否
HY-123849	SN32976	Inhibitor	/	否
HY-N12124	Monascuspiloin	Inhibitor	/	否
HY-153120	PI3K/mTOR Inhibitor-13	Inhibitor	/	否
HY-169121	DA-143	Inhibitor	/	否
HY-N0109R	Salidroside (Standard)	Activator	/	否
HY-162023	mTOR inhibitor-10	Inhibitor	/	否
HY-N13176	Stellettin B	Inhibitor	/	否
HY-164385	NSC126405	Inhibitor	/	否
HY-155211	mTOR inhibitor-13	Inhibitor	/	否
HY-164384	DFX117	Inhibitor	/	否
HY-162024	mTOR inhibitor-16	Inhibitor	/	否
HY-116191	WJD008	Inhibitor	/	否
HY-164662	mTOR inhibitor-24	Inhibitor	/	否
HY-155475	mTORC1-IN-2	Inhibitor	/	否
HY-117923	PF-06465603	Inhibitor	/	否
HY-W779800	D-α-Hydroxyglutaric acid-13C5 disodium	Inhibitor	/	否
HY-162025	mTOR inhibitor-17	Inhibitor	/	否
HY-W654330	Pyraclostrobin-d6		/	否
HY-112602	PI3K/mTOR Inhibitor-1	Inhibitor	/	否
HY-111370	mTOR inhibitor-2	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Mtor	NCBI	NCBI:2475

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.